- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05509088
Impact of the Early Use of High Flow Nasal Cannula in Patients With Post-traumatic Lung Contusion, a Randomized Clinical Trial
August 18, 2022 updated by: Ain Shams University
We hypothesize that early and continuous administration of oxygen via high flow nasal cannula in patients with lung contusion and non-severe acute lung injury might reduce the incidence of intubation and hold the deterioration of pulmonary functions.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: amr hafez, M.D
- Phone Number: 01225674370
- Email: amr_foud@med.asu.edu.eg
Study Contact Backup
- Name: farouk Kamal, M.D
- Email: faroukkamal@med.asu.edu.eg
Study Locations
-
-
-
Cairo, Egypt, 11591
- Recruiting
- Ain shams university hospitals
-
Contact:
- Amr Fouad, MD
- Phone Number: 01225674370
- Email: amr_foud@med.asu.edu.eg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 76 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Willing and able to provide written informed consent prior to performing study procedures, currently hospitalized and requiring medical care for blunt chest trauma, within 24h of trauma
Exclusion Criteria:
- face trauma or surgery, airway obstruction, known to have chronic chest condition
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: high flow nasal cannula
will receive oxygen through high flow nasal cannula
|
Patients in the intervention group receive oxygen through HFNC with a flow rate of set initially at 40 L / min, FiO2 adjusted to maintain SpO2 ≥ 92%, and will be humidified, heated to 34-37 °C, disconnection will be allowed only when ambulation is required, patients will be instructed to practice mouth closing throughout the HFNC therapy as much as possible
|
|
No Intervention: oxygen mask
will receive oxygen through oxygen mask
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
need for intubation and mechanical ventilation within 28 days of randomization.
Time Frame: 3 months
|
the incidence of intubation in patients with lung contusion who receive oxygen through high flow nasal cannula
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 28, 2022
Primary Completion (Anticipated)
December 28, 2022
Study Completion (Anticipated)
December 28, 2022
Study Registration Dates
First Submitted
August 18, 2022
First Submitted That Met QC Criteria
August 18, 2022
First Posted (Actual)
August 19, 2022
Study Record Updates
Last Update Posted (Actual)
August 19, 2022
Last Update Submitted That Met QC Criteria
August 18, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FAMSU R 116/ 2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.